8-K: Terns Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Clinical Program Updates

Terns Pharmaceuticals announced its 2023 financial results, highlighted by a $263 million cash position and progress in clinical trials for its oncology and obesity programs.

Summary

• Terns Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company's cash, cash equivalents, and marketable securities totaled $263.4 million as of December 31, 2023, compared to $283.1 million at the end of 2022.
• Terns expects its current cash reserves to fund operations into 2026.
• Research and development expenses increased to $63.5 million for the year, up from $39.6 million in 2022.
• General and administrative expenses also rose to $39.1 million for the year, compared to $22.4 million in the previous year.
• The company reported a net loss of $90.2 million for the year, compared to a net loss of $60.3 million in 2022.
• Terns is advancing clinical trials for TERN-701, an allosteric BCR-ABL inhibitor for CML, and TERN-601, an oral GLP-1 agonist for obesity.
• Interim data from the TERN-701 Phase 1 trial is expected in the second half of 2024.
• Top-line data from the TERN-601 Phase 1 trial is also expected in the second half of 2024.
• The company has decided to limit spending on MASH programs due to regulatory and clinical development requirements.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive clinical progress and a strong cash position, but also increased losses and expenses. The sentiment is neutral to slightly negative due to the increased losses.

Positives

• The company has a strong cash position of $263.4 million, providing a runway into 2026.
• The initiation of Phase 1 clinical trials for TERN-701 and TERN-601 represents significant progress in their pipeline.
• The FDA's Orphan Drug Designation for TERN-701 is a positive regulatory milestone.
• The appointment of a new CEO, Amy Burroughs, could bring fresh leadership and strategic direction.
• The company is exploring combination therapies for obesity, such as GLP-1 with THRor GIPR modulators.

Negatives

• The company's net loss increased to $90.2 million for the year ended December 31, 2023, compared to $60.3 million in 2022.
• Research and development expenses have increased significantly, indicating higher operational costs.
• General and administrative expenses also increased, contributing to the overall net loss.
• The decision to limit spending on MASH programs may indicate challenges or a shift in strategic focus.

Risks

• The company is dependent on the successful outcome of its clinical trials, which are subject to inherent risks and uncertainties.
• Increased operating expenses, particularly in R&D, could impact the company's financial stability.
• Regulatory hurdles and clinical development requirements for MASH programs could pose challenges.
• The company faces competition in the development of treatments for CML and obesity.
• The company's future success is dependent on the ability to achieve positive clinical data readouts.

Future Outlook

Terns expects its current cash reserves to fund operations into 2026 and anticipates data readouts from its Phase 1 clinical programs for TERN-601 and TERN-701 in the second half of 2024.

Management Comments

• Amy Burroughs, chief executive officer of Terns, stated that she joined Terns at a pivotal stage in the company's growth as they advance towards initial data readouts from their Phase 1 clinical programs.
• Amy Burroughs highlighted that the global Phase 1 trial of TERN-701 allows for the enrollment of second line CML patients, making the study attractive for participants.

Industry Context

Terns is operating in the competitive biopharmaceutical space, focusing on oncology and obesity treatments. The company's approach includes developing small-molecule drugs, which is a common strategy in the industry. The focus on GLP-1 agonists for obesity aligns with current trends in metabolic disease research.

Comparison to Industry Standards

• Terns' cash runway into 2026 is a positive sign, as many biotech companies face funding challenges.
• The increase in R&D spending is typical for a clinical-stage company, but the magnitude of the increase should be monitored.
• The focus on oral small-molecule drugs for GLP-1 is in line with the industry trend to move away from injectables.
• The inclusion of second-line CML patients in the TERN-701 trial is a strategic move to differentiate from competitors.
• Companies like Eli Lilly and Novo Nordisk are also developing GLP-1 agonists for obesity, making this a competitive space.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the clinical progress and cash runway.
• Employees may be impacted by the company's strategic decisions, such as limiting spending on MASH programs.
• Patients with CML and obesity may benefit from the development of new treatment options.
• Creditors and suppliers will be interested in the company's financial stability and cash position.

Next Steps

• Terns will continue to progress its Phase 1 clinical trials for TERN-701 and TERN-601.
• The company plans to host a virtual KOL event in mid-2024 to discuss early CML datasets.
• Terns will continue preclinical efforts to identify promising oral, small-molecule combination candidates for obesity.
• The company will evaluate opportunities for TERN-501 in metabolic diseases.

Key Dates

Keywords

Terns Pharmaceuticals, Clinical Trials, TERN-701, TERN-601, CML, Obesity, GLP-1, BCR-ABL, Orphan Drug Designation, Financial Results